ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

被引：63

作者：

Ledermann, J. A. ^{[1
]}

Matias-Guiu, X. ^{[2
,3
,4
]}

Amant, F. ^{[5
,6
]}

Concin, N. ^{[7
,8
]}

Davidson, B. ^{[9
,10
]}

Fotopoulou, C. ^{[11
]}

Gonzalez-Martin, A. ^{[12
,13
]}

Gourley, C. ^{[14
]}

Leary, A. ^{[15
]}

Lorusso, D. ^{[16
,17
]}

Banerjee, S. ^{[18
,19
]}

Chiva, L. ^{[20
]}

Cibula, D. ^{[21
,22
]}

Colombo, N. ^{[23
,24
]}

Croce, S. ^{[25
]}

Eriksson, A. G. ^{[10
,26
]}

Falandry, C. ^{[27
,28
]}

Fischerova, D. ^{[21
,22
]}

Harter, P. ^{[8
,29
]}

Joly, F. ^{[30
]}

Lazaro, C. ^{[31
]}

Lok, C. ^{[6
]}

Mahner, S. ^{[29
,32
]}

Marme, F. ^{[29
,33
,34
]}

Marth, C. ^{[7
]}

McCluggage, W. G. ^{[35
]}

Mcneish, I. A. ^{[11
]}

Morice, P. ^{[36
]}

Nicum, S. ^{[1
]}

Oaknin, A. ^{[37
]}

Perez-Fidalgo, J. A. ^{[38
]}

Pignata, S. ^{[39
]}

Ramirez, P. T. ^{[40
]}

Ray-Coquard, I. ^{[41
]}

Romero, I. ^{[42
]}

Scambia, G. ^{[16
,17
]}

Sehouli, J. ^{[43
,44
]}

Shapira-Frommer, R. ^{[45
]}

Sundar, S. ^{[46
,47
]}

Tan, D. S. P. ^{[48
,49
,50
,51
]}

Taskiran, C. ^{[38
]}

van Driel, W. J. ^{[40
]}

Vergote, I. ^{[52
]}

Planchamp, F. ^{[37
]}

Sessa, C. ^{[48
,49
,50
,51
]}

Fagotti, A. ^{[6
]}

机构：

[1] UCL, UCL Canc Inst, Dept Oncol, London, England

[2] CIBERONC, Madrid, Spain

[3] Univ Lleida, Hosp Univ Arnau Vilanova, Dept Pathol, IRBLLEIDA, Lleida, Spain

[4] Univ Barcelona, Hosp Univ Bellvitge, Dept Pathol, IDIBELL, Barcelona, Spain

[5] Univ Hosp Leuven, Leuven Canc Inst, Dept Gynaecol Oncol, Leuven, Belgium

[6] Netherlands Canc Inst, Ctr Gynecol Oncol Amsterdam, Dept Gynecol, Amsterdam, Netherlands

[7] Med Univ Innsbruck, Dept Obstet & Gynaecol, Innsbruck, Austria

[8] Evang Kliniken Essen Mitte, Dept Gynaecol & Gynaecol Oncol, Essen, Germany

[9] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway

[10] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway

[11] Imperial Coll London, Fac Med, Dept Surg & Canc, London, England

[12] Clin Univ Navarra, Canc Ctr, Dept Med Oncol, Madrid, Spain

[13] Clin Univ Navarra, Canc Ctr, Program Solid Tumours Cima, Madrid, Spain

[14] Univ Edinburgh, Inst Genet & Canc, Canc Res UK Scotland Ctr, Edinburgh, Midlothian, Scotland

[15] Inst Gustave Roussy, Dept Med, Villejuif, France

[16] Fdn Policlin Univ A Gemelli IRCCS, Div Gynecol Oncol, Rome, Italy

[17] Univ Cattolica Sacro Cuore, Dept Woman Child & Publ Hlth, Rome, Italy

[18] Royal Marsden NHS Fdn Trust, London, England

[19] Inst Canc Res, London, England

[20] Clin Univ Navarra, Dept Gynaecol & Obstet, Canc Ctr, Navarra, Spain

[21] Charles Univ Prague, Fac Med 1, Dept Gynecol Obstet & Neonatol, Prague, Czech Republic

[22] Gen Univ Hosp Prague, Prague, Czech Republic

[23] Ist Europeo Oncol IRCCS, Dept Gynecol Oncol, Milan, Italy

[24] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy

[25] Bergonie Inst, Dept Biopathol, Bordeaux, France

[26] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, Div Canc Med, Oslo, Norway

[27] Hosp Civils Lyon, Inst Aging, Lyon, France

[28] Univ Lyon 1, CarMeN Lab, INSERM,U1060, INRAE,U1397,Hosp Civils Lyon, Pierre Benite, France

[29] Arbeitsgemeinschaft Gynakol Onkol AGO Study Grp, Ravensburg, Germany

[30] Univ Caen Normandy, Ctr Francois Baclesse, Dept Med Oncol, GINECO Grp, Caen, France

[31] CIBERONC, Hereditary Canc Program, Catalan Inst Oncol, ICO,IDIBELL, Barcelona, Spain

[32] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Obstet & Gynecol, Munich, Germany

[33] Univ Hosp Mannheim, Dept Obstet & Gynecol, Mannheim, Germany

[34] Heidelberg Univ, Med Fac Mannheim, Mannheim, Germany

[35] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland

[36] Gustave Roussy Canc Campus, Dept Gynecol Surg, Villejuif, France

[37] Hosp Univ Vall Hebron, Gynaecol Canc Programme, Vall Hebron Inst Oncol VHIO, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain

[38] Hosp Clin Univ, Dept Med Oncol, INCLIVA, CIBERONC, Valencia, Spain

[39] IRCCS Fdn Pascale, Ist Nazl Tumori Napoli, Dept Urol & Gynecol, Naples, Italy

[40] Houston Methodist Hosp, Dept Obstet & Gynecol, Houston, TX USA

[41] Univ Claude Bernard, Ctr Leon Berard, Dept Med Oncol, Lyon, France

[42] Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain

[43] North Eastern German Soc Gynecol Oncol NOGGO, Berlin, Germany

[44] Charite Berlin Univ Med, Ctr Oncol Surg, Dept Gynecol, Berlin, Germany

[45] Sheba Med Ctr, Ramat Gan, Israel

[46] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England

[47] City Hosp, Pan Birmingham Gynaecol Canc Ctr, Birmingham, W Midlands, England

[48] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore

[49] Natl Univ Singapore, Natl Univ Singapore NUS Ctr Canc Res, Yong Loo Lin Sch Med, Singapore, Singapore

[50] Natl Univ Singapore, Canc Sci Inst, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 03期

关键词：

chemotherapy; maintenance treatment; molecular biology; ovarian cancer; pathology; surgery; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; TUBAL INTRAEPITHELIAL CARCINOMA; SEROUS BORDERLINE TUMORS; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; ADJUVANT CHEMOTHERAPY; MAINTENANCE THERAPY; FALLOPIAN-TUBE; OPEN-LABEL; QUALITY INDICATORS;

D O I：

10.1016/j.annonc.2023.11.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early -stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.

引用

页码：248 / 266

页数：19

共 111 条

[41] A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma
Hannibal, Charlotte Gerd
Vang, Russell
Junge, Jette
Frederiksen, Kirsten
Kurman, Robert J.
Kjaer, Susanne K.
[J]. GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 174 - 180
[42] Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Harter, P.
Sehouli, J.
Vergote, I
Ferron, G.
Reuss, A.
Meier, W.
Greggi, S.
Mosgard, B. J.
Selle, F.
Guyon, F.
Pomel, C.
Lecuru, F.
Zang, R.
Avail-Lundqvist, E.
Kim, J-W
Ponce, J.
Raspagliesi, F.
Kristensen, G.
Classe, J-M
Hillemanns, P.
Jensen, P.
Hasenburg, A.
Ghaem-Maghami, S.
Mirza, M. R.
Lund, B.
Reinthaller, A.
Santaballa, A.
Olaitan, A.
Hilpert, F.
du Bois, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (23) : 2123 - 2131
[43] A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Harter, Philipp
Sehouli, Jalid
Lorusso, Domenica
Reuss, Alexander
Vergote, Ignace
Marth, Christian
Kim, Jae-Weon
Raspagliesi, Francesco
Lampe, Bjoern
Aletti, Giovanni
Meier, Werner
Cibula, David
Mustea, Alexander
Mahner, Sven
Runnebaum, Ingo B.
Schmalfeldt, Barbara
Burges, Alexander
Kimmig, Rainer
Scambia, Giovanni
Greggi, Stefano
Hilpert, Felix
Hasenburg, Annette
Hillemanns, Peter
Giorda, Giorgio
von Leffern, Ingo
Schade-Brittinger, Carmen
Wagner, Uwe
du Bois, Andreas
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (09) : 822 - 832
[44] Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer
Hodan, Rachel
Kingham, Kerry
Cotter, Kristina
Folkins, Ann K.
Kurian, Allison W.
Ford, James M.
Longacre, Teri
[J]. CANCER MEDICINE, 2021, 10 (03): : 1012 - 1017
[45] Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Jaeschke, Roman
Guyatt, Gordon H.
Dellinger, Phil
Schunemann, Holger
Levy, Mitchell M.
Kunz, Regina
Norris, Susan
Bion, Julian
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7665): : a744
[46] Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients
Jorgensen, Trine Lembrecht
Teiblum, Sandra
Paludan, Merete
Poulsen, Laurids Ostergaard
Jorgensen, Anni Young Stensgard
Bruun, Karin Herskind
Hallas, Jesper
Herrstedt, Jorn
[J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (02) : 367 - 374
[47] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Kehoe, Sean
Hook, Jane
Nankivell, Matthew
Jayson, Gordon C.
Kitchener, Henry
Lopes, Tito
Luesley, David
Perren, Timothy
Bannoo, Selina
Mascarenhas, Monica
Dobbs, Stephen
Essapen, Sharadah
Twigg, Jeremy
Herod, Jonathan
McCluggage, Glenn
Parmar, Mahesh
Swart, Ann-Marie
[J]. LANCET, 2015, 386 (9990) : 249 - 257
[48] Survival in Advanced-Stage Epithelial Ovarian Cancer Patients with Cardiophrenic Lymphadenopathy Who Underwent Cytoreductive Surgery: A Systematic Review and Meta-Analysis
Kengsakul, Malika
Nieuwenhuyzen-de Boer, Gatske M.
Bijleveld, Anna H. J.
Udomkarnjananun, Suwasin
Kerr, Stephen J.
Niehot, Christa D.
van Beekhuizen, Heleen J.
[J]. CANCERS, 2021, 13 (19)
[49] An update on the role of PET/CT and PET/MRI in ovarian cancer
Khiewvan, Benjapa
Torigian, Drew A.
Emamzadehfard, Sahra
Paydary, Koosha
Salavati, Ali
Houshmand, Sina
Werner, Thomas J.
Alavi, Abass
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1079 - 1091
[50] Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK
Khoja, L.
Nolan, K.
Mekki, R.
Milani, A.
Mescallado, N.
Ashcroft, L.
Hasan, J.
Edmondson, R.
Winter-Roach, B.
Kitchener, H. C.
Mould, T.
Hutson, R.
Hall, G.
Clamp, A. R.
Perren, T.
Ledermann, J.
Jayson, G. C.
[J]. CLINICAL ONCOLOGY, 2016, 28 (12) : 760 - 765

← 1 2 3 4 5 6 7 8 9 10 →